BioAegis Therapeutics' Convertible Note - II Round

BioAegis Therapeutics raised a round of funding on February 07, 2014.

BioAegis Therapeutics is developing a portfolio of biomarker-directed treatments across a range of indications. The company's products aim to restore depleted levels of plasma gelsolin, an integral an…

Articles about BioAegis Therapeutics' Convertible Note - II Round: